Posted by Michael Wonder on 23 Jun 2026
FDA grants rolling review of Palvella’s Qtorin rapamycin NDA for microcystic lymphatic malformations
22 June 2026 - Palvella Therapeutics announced today that FDA has granted rolling review for the Company’s new drug application for Qtorin rapamycin for the treatment of microcystic lymphatic malformations.
Qtorin rapamycin has received breakthrough therapy, orphan drug and fast track designations from FDA for the treatment of microcystic lymphatic malformations.
